NCT02644369View on ClinicalTrials.gov

Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 21, 2016

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Squamous Cell Cancer of Head and NeckTriple Negative Breast CancerEpithelial Ovarian CancerMalignant MelanomaAdvanced Solid Tumors
Interventions
BIOLOGICAL

Pembrolizumab

Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University Health Network, Toronto

OTHER